Acumen Pharmaceuticals Inc ABOS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
-
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
-
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
-
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
-
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
-
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
-
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 52
- Website
- https://www.acumenpharm.com
Comparables
Valuation
|
Metric
|
ABOS
|
EXEL
|
FULC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.20 | — |
Price/Book Value | 0.60 | 3.53 | 0.91 |
Price/Sales | — | 4.01 | 3.08 |
Price/Cash Flow | — | 16.42 | — |
Price/Earnings
ABOS
EXEL
FULC
Financial Strength
|
Metric
|
ABOS
|
EXEL
|
FULC
|
|---|---|---|---|
Quick Ratio | 16.96 | 4.05 | 21.84 |
Current Ratio | 17.37 | 4.27 | 22.07 |
Interest Coverage | — | — | — |
Quick Ratio
ABOS
EXEL
FULC
Profitability
|
Metric
|
ABOS
|
EXEL
|
FULC
|
|---|---|---|---|
Return on Assets (Normalized) | −20.78% | 14.82% | −1.76% |
Return on Equity (Normalized) | −23.19% | 19.05% | −1.91% |
Return on Invested Capital (Normalized) | −26.40% | 14.99% | −1.83% |
Return on Assets
ABOS
EXEL
FULC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tqdqchzqk | Pfnw | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hklyjrnc | Gxmbhd | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Trstscy | Dshmw | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vxytxqlw | Rlwqw | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Mtsmtpfj | Qtqs | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Kfxfwvt | Wmw | $28.0 Bil | |||
| Moderna Inc
MRNA
| Wtkxrnls | Dwgc | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Ggfjvmsz | Kmh | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dttfkjtz | Ykjlc | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Nrjsjbctks | Zslklp | $12.6 Bil |
United States